142 related articles for article (PubMed ID: 36896482)
1. First donor haemovigilance system at a national level in China: Establishment and improvement.
Yang J; Fan D; Xie D; Guo X; Zhu W; He T; Huang X
Vox Sang; 2023 May; 118(5):357-366. PubMed ID: 36896482
[TBL] [Abstract][Full Text] [Related]
2. The International Haemovigilance Network Database for the Surveillance of Adverse Reactions and Events in Donors and Recipients of Blood Components: technical issues and results.
Politis C; Wiersum JC; Richardson C; Robillard P; Jorgensen J; Renaudier P; Faber JC; Wood EM
Vox Sang; 2016 Nov; 111(4):409-417. PubMed ID: 27658188
[TBL] [Abstract][Full Text] [Related]
3. Development of standard definitions for surveillance of complications related to blood donation.
Goldman M; Land K; Robillard P; Wiersum-Osselton J
Vox Sang; 2016 Feb; 110(2):185-8. PubMed ID: 26361365
[TBL] [Abstract][Full Text] [Related]
4. Complications of blood donation reported to haemovigilance systems: analysis of eleven years of international surveillance.
Wiersum-Osselton JC; Politis C; Richardson C; Goto N; Grouzi E; Marano G; Land KJ
Vox Sang; 2021 Jul; 116(6):628-636. PubMed ID: 33278040
[TBL] [Abstract][Full Text] [Related]
5. Haemovigilance resources available for everyone: A report from the International Haemovigilance Tools Collaborative Project.
Townsend M; Maryuningsih Soedarmono YS; Narayan S; Ashford P; Wood EM; Whitaker BI
Vox Sang; 2024 Mar; 119(3):277-281. PubMed ID: 38126141
[TBL] [Abstract][Full Text] [Related]
6. Online reporting system for transfusion-related adverse events to enhance recipient haemovigilance in Japan: a pilot study.
Odaka C; Kato H; Otsubo H; Takamoto S; Okada Y; Taneichi M; Okuma K; Sagawa K; Hoshi Y; Tasaki T; Fujii Y; Yonemura Y; Iwao N; Tanaka A; Okazaki H; Momose SY; Kitazawa J; Mori H; Matsushita A; Nomura H; Yasoshima H; Ohkusa Y; Yamaguchi K; Hamaguchi I
Transfus Apher Sci; 2013 Feb; 48(1):95-102. PubMed ID: 22954634
[TBL] [Abstract][Full Text] [Related]
7. International haemovigilance: what have we learned and what do we need to do next?
Wood EM; Ang AL; Bisht A; Bolton-Maggs PH; Bokhorst AG; Flesland O; Land K; Wiersum-Osselton JC; Schipperus MR; Tiberghien P; Whitaker BI
Transfus Med; 2019 Aug; 29(4):221-230. PubMed ID: 30729612
[TBL] [Abstract][Full Text] [Related]
8. [Delayed adverse reactions to blood donation: From haemovigilance data to specific studies].
Py JY; Durieux S; Barnoux M; Sapey T
Transfus Clin Biol; 2016 Nov; 23(4):233-239. PubMed ID: 27769684
[TBL] [Abstract][Full Text] [Related]
9. Development of the Chinese Haemovigilance Network and reporting of adverse transfusion reactions from 2018 to 2020.
Tian X; Kong Y; Wang J; He R; Li L; Liu Z;
Vox Sang; 2022 Aug; 117(8):1027-1034. PubMed ID: 35560059
[TBL] [Abstract][Full Text] [Related]
10. Blood donor haemovigilance in Yaoundé, Cameroon.
Nchinda EC; Tagny CT; Mbanya D
Transfus Med; 2012 Aug; 22(4):257-61. PubMed ID: 22630141
[TBL] [Abstract][Full Text] [Related]
11. The new donor vigilance system in Denmark reveals regional differences in adverse reactions supposedly caused by variation in the registration.
Mikkelsen C; Paarup HM; Bruun MT; Pedersen LØ; Hasslund S; Larsen R; Aagaard B; Sørensen BS
Vox Sang; 2022 Mar; 117(3):321-327. PubMed ID: 34523137
[TBL] [Abstract][Full Text] [Related]
12. Eight years with haemovigilance in Norway. What have we learnt?
Steinsvåg CT; Espinosa A; Flesland Ø
Transfus Apher Sci; 2013 Dec; 49(3):548-52. PubMed ID: 24157220
[TBL] [Abstract][Full Text] [Related]
13. Vasovagal reactions in whole blood and apheresis donors: a cross-sectional study on donor haemovigilance data from 2016 to 2019 in Italy.
Piccinini V; Marano G; Catalano L; Pati I; Veropalumbo E; de Waure C; Pupella S; De Angelis V
Blood Transfus; 2022 Jul; 20(4):281-291. PubMed ID: 34694220
[TBL] [Abstract][Full Text] [Related]
14. Post-donation information and haemovigilance reporting for COVID-19 in Greece: Information supporting the absence of SARS-CoV-2 possible transmission through blood components.
Politis C; Papadaki M; Politi L; Kourti G; Richardson C; Asariotou M; Tsakris A; Mentis A
Transfus Clin Biol; 2021 Feb; 28(1):55-59. PubMed ID: 33096208
[TBL] [Abstract][Full Text] [Related]
15. [Single-donor (apheresis) platelets and pooled whole-blood-derived platelets--significance and assessment of both blood products].
Hitzler WE
Clin Lab; 2014; 60(4):S1-39. PubMed ID: 24779310
[TBL] [Abstract][Full Text] [Related]
16. First annual report of Chinese haemovigilance network.
Yin Y; Tian X; Li L; Kong Y; Wang J; Lin F; Song N; Chen Q; Gan J; Peng T; Li X; Wu Y; Ge H; Wang H; Jiang J; Bai L; Ji H; Zhao G; Huang Y; Liu Z;
Vox Sang; 2021 Jul; 116(6):718-724. PubMed ID: 33423307
[TBL] [Abstract][Full Text] [Related]
17. Haemovigilance: an effective tool for improving transfusion practice.
de Vries RR; Faber JC; Strengers PF;
Vox Sang; 2011 Jan; 100(1):60-7. PubMed ID: 21175656
[TBL] [Abstract][Full Text] [Related]
18. How we forecast tomorrow's haemovigilance.
Wood EM; Whitaker BI; Townsend M; Narayan S
Transfus Clin Biol; 2024 May; 31(2):114-118. PubMed ID: 38460837
[TBL] [Abstract][Full Text] [Related]
19. Adverse reactions following transfusion of blood components, with a focus on some rare reactions: Reports to the International Haemovigilance Network Database (ISTARE) in 2012-2016.
Politis C; Wiersum-Osselton J; Richardson C; Grouzi E; Sandid I; Marano G; Goto N; Condeço J; Boudjedir K; Asariotou M; Politi L; Land K
Transfus Clin Biol; 2022 Aug; 29(3):243-249. PubMed ID: 35476961
[TBL] [Abstract][Full Text] [Related]
20. Estimating the residual risk for HIV, HCV and HBV in different types of platelet concentrates in Germany.
an der Heiden M; Ritter S; Hamouda O; Offergeld R
Vox Sang; 2015 Feb; 108(2):123-30. PubMed ID: 25335096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
